GSK3B and cancer: Regarding the subject #39, the initial screening detected a clone containing the mutation in CTNNB1 (c.109T > G), but the cancer developed from a clone carrying a different CTNNB1 mutation (c.97T > G); both mutations are located at the GSK3β phosphorylation sites and are thus supposed to render resistance to its degradation.